Citigroup’s ImmunityBio IBRX Stock Holding History

Citigroup’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$384K	Buy	+50,000	New	+$342K	﹤0.01%	3695

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citigroup's IBRX Position: Q1 2026 in Review

Citigroup increased its ImmunityBio (IBRX) stake by 52% in Q1 2026, buying an estimated $396K and bringing the position to 168,356 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2953.

Citigroup first reported a position in IBRX in Q3 2015 and has held it in 43 quarters since. The position peaked at $8.17M in Q1 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Citigroup held 168,356 shares of ImmunityBio worth $1.29M as of Q1 2026.
Citigroup bought 57,845 ImmunityBio shares in Q1 2026, an estimated $396K.
ImmunityBio made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2953 holding.
Citigroup first reported a position in ImmunityBio in Q3 2015 and has held it in 43 quarters since.
Citigroup's ImmunityBio position peaked at $8.17M in Q1 2025.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.